ReviewJournal of the renin-angiotensin-aldosterone system : JRAAS2022
View of the Renin-Angiotensin System in Acute Kidney Injury Induced by Renal Ischemia-Reperfusion Injury.
Review in Journal of the renin-angiotensin-aldosterone system : JRAAS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Elevated serum creatinine over the first week of life and mortality risk in extremely preterm neonates: a secondary analysis of the Preterm Erythropoietin Neuroprotection Trial (PENUT).Pediatric nephrology (Berlin, Germany) · 2026Trial
- Protective Arm of Renin-Angiotensin System: Evidence of Nephroprotective Effects Against Acute Kidney Injury.Acta physiologica (Oxford, England) · 2026Review
- Relationship Between Fall Risk and Risk of Acute Kidney Injury in Patients with Acute Myocardial Infarction: A Multicenter Retrospective Study.Clinical interventions in aging · 2026Article
- The role of endothelin receptor antagonists in kidney disease.Renal failure · 2025Review
- Serum angiotensinogen as a biomarker for renal outcomes in patients with acute myocardial infarction: prognostic significance and clinical implications.BMC nephrology · 2025Observational
- Article
- Role of AT1angiotensin receptor antagonist in pulmonary complications induced by renal ischemia-reperfusion injury in male and female rats.BMC nephrology · 2025Article
- Identification of Ferroptosis-Related Genes in Patients with Renal Ischemia-Reperfusion Injury.International journal of general medicine · 2025Article
- Role of G protein coupled receptors in acute kidney injury.Cell communication and signaling : CCS · 2024Review
- Exposure to renin-angiotensin system inhibitors before kidney transplantation is associated with a decreased risk of delayed graft function.Frontiers in immunology · 2024Article
- Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.Journal of the American Heart Association · 2023Review
- A comprehensive review of acute cardio-renal syndrome: need for novel biomarkers.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal ischemia-reperfusion injury (RIRI) is a sequence of complicated events that is defined as a reduction of the blood supply followed by reperfusion. RIRI is the leading cause of acute kidney injury (AKI). Among the diverse mediators that take part in RIRI-induced AKI, the renin-angiotensin system (RAS) plays an important role via conventional (angiotensinogen, renin, angiotensin-converting enzyme (ACE), angiotensin (Ang) II, and Ang II type 1 receptor (AT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.